Adderall XR Cost in Vermont 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is the Cash Price for Adderall XR in Vermont in 2026?

The average cash-pay price for generic Adderall XR at Vermont retail pharmacies in 2026 runs approximately $30 per month when a free discount card (GoodRx, RxSaver, or similar) is applied at the point of sale. Without any discount, the same prescription can ring up closer to the $260 manufacturer list price for branded Teva product.

That $230 gap between list price and discounted cash price is one of the widest in the ADHD medication category, and it exists because aggressive pharmacy-benefit negotiation by pharmacy benefit managers has pushed generic mixed amphetamine salts into a low-cost tier at most major chains. Pharmacies in Burlington, Montpelier, Rutland, and smaller Vermont towns all participate in third-party discount networks, so geography within the state rarely changes the final price by more than a few dollars.

A 30-capsule supply of 20 mg generic mixed amphetamine salts XR at a national chain in Vermont currently runs between $28 and $34 with a discount card. Dosages of 5 mg, 10 mg, 15 mg, 25 mg, and 30 mg fall in a similar range. Higher doses (25 mg, 30 mg) may carry a slight premium of $3 to $6 per fill due to lower dispensing volume.

To get the best cash price: present the discount card before the pharmacist processes the claim, confirm the pharmacy is dispensing a generic (not the Teva brand), and ask for a 90-day supply if your clinician is willing to write that quantity, since cost-per-capsule often drops by 10 to 15 percent on a 90-day fill.

FDA labeling for mixed amphetamine salts extended-release is accessible at the FDA Drugs database, and prescribers in Vermont must comply with all Schedule II record-keeping and prescribing rules outlined there.

Does Vermont Medicaid Cover Adderall XR?

Vermont Medicaid (Green Mountain Care) covers Adderall XR for both ADHD and narcolepsy, but the prescription requires prior authorization (PA) before the first fill is approved. The PA process typically asks the prescriber to document an ADHD diagnosis meeting DSM-5 criteria, prior treatment history, and clinical rationale for the XR (extended-release) formulation over immediate-release alternatives.

PA approval for pediatric ADHD patients (ages 6 to 17) generally moves faster than adult approvals because the ADHD diagnosis is more established in the pediatric literature. The landmark MTA Cooperative Group study (N=579, published in Archives of General Psychiatry, 1999) showed that carefully managed stimulant medication produced significantly better ADHD symptom outcomes than behavioral therapy alone at 14 months. That study remains a foundational reference that Vermont Medicaid reviewers recognize when evaluating PA requests for stimulants. The full MTA trial is indexed at PubMed.

For adults, PA reviewers may ask for documentation that at least one non-stimulant agent (such as atomoxetine or viloxazine) was considered or tried, particularly if there is any history of substance use disorder in the record. Vermont has implemented opioid and controlled-substance prescribing guidelines that apply broadly to Schedule II drugs, and those guidelines influence how PA reviewers evaluate stimulant requests.

Once PA is approved, Vermont Medicaid members pay $0 to $3 per fill under the standard Green Mountain Care cost-sharing schedule, making it by far the lowest-cost access pathway in the state. PA approvals are typically valid for 12 months and must be renewed annually with updated clinical documentation.

Providers who have prescriptive authority in Vermont and are enrolled as Medicaid providers can submit PA requests through the Vermont Medicaid online portal or via phone. Turnaround time averages 3 to 5 business days for standard reviews and 24 hours for urgent reviews when a prior PA had lapsed and the patient is currently on therapy.

Which Private Insurance Plans in Vermont Cover Adderall XR?

Most commercial plans offered through Vermont Health Connect (the state ACA marketplace) and employer-sponsored plans in Vermont place generic mixed amphetamine salts on Tier 1 or Tier 2 of the drug formulary, which means a typical copay runs $10 to $45 per 30-day supply depending on plan design.

Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna (for large group plans with Vermont members) all listed generic mixed amphetamine salts as covered on their 2024 to 2026 formularies, with prior authorization required for doses above 30 mg/day and for patients over age 18 in some plan designs. Confirm the exact PA threshold with your specific plan, since formulary tiers and PA thresholds can shift at each annual plan year.

The branded Teva Adderall XR product sits on Tier 3 or a non-preferred brand tier at most Vermont plans, pushing the out-of-pocket cost to $60 to $120 per fill before the deductible is met. Generic is the financially rational choice for nearly every insured Vermont patient unless there is a documented reason to use brand.

If your plan has a high deductible and you are still in the deductible phase early in the year, the cash-pay discount-card price ($30) will often beat what you would pay under insurance until you cross the deductible threshold. Running both pathways and picking the lower one at each fill is legal and practical under current Vermont pharmacy rules.

The HealthRX 3-Step Vermont Adderall XR Cost Decision Framework:

1. Check whether your income qualifies for Vermont Medicaid (Green Mountain Care). If yes, pursue PA immediately since the net cost approaches $0.
2. If privately insured, confirm your plan's current formulary tier for the NDC of the specific generic your pharmacy stocks. If the copay exceeds $30, switch to the discount-card cash-pay pathway for that fill.
3. If uninsured or self-pay, use a discount card at the point of sale and ask for 90-day fills when clinically appropriate to reduce per-capsule cost.

Are Compounded Mixed Amphetamine Salts Legal in Vermont?

Compounded mixed amphetamine salts are legal in Vermont when prepared by a state-licensed pharmacy operating under the federal 503A framework. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. Vermont's Board of Pharmacy enforces both state compounding regulations and compliance with FDA guidance on compounded controlled substances.

The practical significance is real. Some patients in Vermont pay $0 per month for compounded mixed amphetamine salts through specific telehealth platforms that work with 503A-licensed compounding pharmacies, compared with $30 at retail for generic or up to $260 for branded product. The catch is that the compounded product is not FDA-approved and does not carry the same bioequivalence data as the reference drug. Quality, potency, and sterility depend entirely on the individual 503A pharmacy's practices and inspection record.

Before choosing a compounded stimulant, ask the prescribing clinician to confirm the pharmacy holds a current Vermont Board of Pharmacy license and has passed a recent inspection. The FDA's guidance on compounded drug products explains the legal distinction between 503A patient-specific compounding and the larger 503B outsourcing facilities that supply hospitals.

Patients should also understand that compounded Schedule II controlled substances carry the same DEA and state regulatory requirements as any other Schedule II prescription. The compounding pharmacy must have a DEA Schedule II registration, and the prescribing clinician must issue a written prescription (electronic prescriptions for Schedule II are permitted in Vermont under DEA e-prescribing rules that took effect nationally in 2021).

Research published through NIH's drug information network consistently flags the importance of bioavailability data when switching between formulations of mixed amphetamine salts, particularly for extended-release vs. immediate-release profiles. Discuss any formulation switch with your prescriber before changing from a commercially approved product to a compounded alternative.

Can Vermont Patients Get Adderall XR via Telehealth?

Telehealth prescribing of Adderall XR is permitted in Vermont as of 2026. The temporary DEA telemedicine exemption that allowed Schedule II prescribing without an in-person visit, first granted during the COVID-19 public health emergency, has been extended through a series of DEA proposed rules that Vermont providers and telehealth platforms have operated under.

Vermont's own telemedicine statute (33 V.S.A. Chapter 39) does not impose additional barriers beyond the DEA framework for Schedule II prescribing via telehealth. Clinicians must hold a valid DEA registration in Vermont, must conduct a real-time audio-visual evaluation (audio-only is not sufficient for a new Schedule II prescription under current DEA guidance), and must comply with Vermont's prescription monitoring program (PMP) requirements, including a mandatory PMP check before prescribing any Schedule II controlled substance.

Patients establishing care through telehealth for ADHD in Vermont can expect a visit that includes a structured clinical interview, a standardized ADHD rating scale (such as the Adult ADHD Self-Report Scale or Conners Rating Scale), a review of current medications, and a PMP check. The whole process typically takes 45 to 60 minutes for a first appointment.

HealthRX operates in Vermont and can connect patients with board-certified clinicians for ADHD evaluation. After a successful evaluation, a prescription is sent electronically to a Vermont pharmacy of the patient's choice. Follow-up appointments to monitor response, side effects, and dose titration are required at intervals of 30 to 90 days, depending on clinical stability.

A 2023 review indexed on PubMed examined telehealth ADHD care delivery and found that patient-reported access to treatment improved significantly in states that maintained flexible telehealth prescribing rules after the pandemic, with treatment initiation rates rising by roughly 15% in flexible states versus a 3% rise in states with stricter in-person requirements.

What Are the Standard Dosing and Formulation Details for Adderall XR?

Adderall XR (mixed amphetamine salts, extended-release) contains a 75:25 ratio of dextroamphetamine to levoamphetamine salts. The capsule uses a dual-bead delivery system: half the beads release immediately, mimicking an immediate-release dose, and the remaining beads release approximately 4 hours later, extending coverage to 8 to 12 hours with a single morning dose.

The FDA-approved dosing for ADHD in adults starts at 20 mg once daily in most clinical protocols, though the label permits starting at 5 mg or 10 mg when tolerability is a concern. Maximum approved dose is 30 mg/day for adults. For children ages 6 to 12, starting doses of 5 to 10 mg/day are standard, with titration upward in 5 mg to 10 mg increments at weekly intervals based on response and tolerability. The full prescribing information is available at the FDA drug database.

Common side effects documented in clinical trials include decreased appetite (reported in 22 to 35% of patients in controlled trials), insomnia (11 to 17%), dry mouth (35% in adults), and elevated heart rate (6 to 14% depending on dose). Blood pressure increases of 2 to 4 mmHg systolic have been consistently observed across trials. Patients with pre-existing cardiovascular disease, structural cardiac abnormalities, or uncontrolled hypertension require careful risk-benefit discussion before starting any amphetamine-based therapy.

The American Heart Association's scientific statement on cardiovascular safety of ADHD medications supports baseline cardiovascular assessment before stimulant initiation and periodic monitoring thereafter. Vermont clinicians generally follow this guidance regardless of whether care is delivered in-person or via telehealth.

Vermont ADHD Epidemiology: Why This Matters for Access Planning

Vermont's ADHD prevalence data from the CDC's 2022 National Survey of Children's Health placed Vermont at approximately 8.7% diagnosed ADHD among children ages 3 to 17. The CDC's ADHD data page tracks state-level prevalence and shows Vermont slightly below the national average of 9.8% for that age group.

Adult ADHD in Vermont is less precisely tracked by state-level data, but national estimates consistently place adult prevalence at 4 to 5% of the population. With Vermont's 2024 estimated population of approximately 648,000, that translates to roughly 19,000 to 26,000 Vermont adults who may meet diagnostic criteria. A meaningful fraction of those adults remain undiagnosed or undertreated, in part because primary care access in rural Vermont counties (Essex, Orleans, Caledonia) can be limited.

Telehealth has meaningfully widened that access gap. Short wait times for telehealth ADHD evaluations (often 3 to 7 days versus 6 to 12 weeks at in-person psychiatry practices in Vermont) reduce the period during which patients with untreated ADHD experience functional impairment at work, in school, and in personal relationships.

Research in the Journal of the American Medical Association (JAMA) has documented the occupational and educational productivity losses associated with untreated adult ADHD, estimating annual lost productivity in the range of $4,000 to $7,000 per untreated adult. The cost of a $30 monthly generic prescription is negligible relative to those downstream costs.

How Discount Cards Work at Vermont Pharmacies

Discount cards (GoodRx, RxSaver, NeedyMeds, Blink Health) function as third-party price negotiators. They are not insurance. They provide a discount code that the pharmacist enters at the point of sale, and the pharmacy accepts a lower dispensing fee in exchange for the card network's volume commitments with that chain or independent pharmacy.

In Vermont, these cards are accepted at national chains (CVS, Walgreens, Rite Aid) and at most independent pharmacies that participate in the underlying pharmacy benefit network. A few small independent pharmacies in rural Vermont counties may not participate in all card networks, so calling ahead to confirm acceptance before driving a long distance makes sense.

For Adderall XR specifically, discount card prices in Vermont as of mid-2025 ranged from $27 to $38 for a 30-day supply of 20 mg generic, depending on which network the pharmacy was enrolled in at time of processing. These prices shift month to month based on generic manufacturer competition, so checking the card platform's online price tool the day before filling gives the most accurate estimate.

Manufacturer savings programs (like Teva's savings card for the branded Adderall XR product) typically exclude patients covered by federal or state government insurance (Medicaid, Medicare, CHIP, TRICARE). Vermont Medicaid patients are not eligible for manufacturer copay cards. However, uninsured Vermont residents and those with commercial insurance are generally eligible to use them.

The FDA's patient assistance resources page lists legitimate patient assistance program contacts for major manufacturers, which is a useful starting point for patients whose income may qualify them for free medication through Teva's patient assistance program.